Ullah, Tomalika R. http://orcid.org/0000-0002-5935-6939
Johansen, Matt D. http://orcid.org/0000-0001-5553-5270
Balka, Katherine R. http://orcid.org/0000-0003-0643-3360
Ambrose, Rebecca L.
Gearing, Linden J. http://orcid.org/0000-0003-3508-3056
Roest, James
Vivian, Julian P.
Sapkota, Sunil
Jayasekara, W. Samantha N.
Wenholz, Daniel S.
Aldilla, Vina R.
Zeng, Jun
Miemczyk, Stefan http://orcid.org/0000-0003-1462-3850
Nguyen, Duc H.
Hansbro, Nicole G.
Venkatraman, Rajan
Kang, Jung Hee
Pang, Ee Shan
Thomas, Belinda J.
Alharbi, Arwaf S. http://orcid.org/0000-0003-3694-1067
Rezwan, Refaya
O’Keeffe, Meredith http://orcid.org/0000-0002-0779-4654
Donald, William A. http://orcid.org/0000-0002-6622-8193
Ellyard, Julia I. http://orcid.org/0000-0001-6301-2533
Wong, Wilson
Kumar, Naresh
Kile, Benjamin T.
Vinuesa, Carola G. http://orcid.org/0000-0001-9799-0298
Kelly, Graham E.
Laczka, Olivier F. http://orcid.org/0000-0003-0966-9897
Hansbro, Philip M. http://orcid.org/0000-0002-4741-3035
De Nardo, Dominic http://orcid.org/0000-0002-7045-4695
Gantier, Michael P. http://orcid.org/0000-0003-3740-698X
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (2011467, 1175134, 1113577)
Department of Education and Training | Australian Research Council (140100594)
Article History
Received: 2 January 2023
Accepted: 3 September 2023
First Online: 18 September 2023
Competing interests
: Financial competing interests: O.F.L. and D.S.W. are employees of Noxopharm. G.E.K. owns equity in Noxopharm. M.P.G., J.Z., J.I.E., V.R.A., N.K. and P.M.H. receive funding from Noxopharm Ltd. to study the activity of IDX in inflammation. M.P.G. and P.M.H. received consulting fees from Noxopharm Ltd. Noxopharm Ltd. was involved in the conceptualisation, design, data collection, analysis and helped the preparation of the manuscript. M.P.G., J.Z., V.R.A., N.K., J.I.E. and P.M.H. do not personally own shares and/or equity in Noxopharm Ltd. G.E.K., O.F.L. and M.P.G. are named inventors of a patent (assignee: Noxopharm Ltd) relating to the use of IDX to treat inflammation associated with infection (WO/2021/195698, including patent US20210299085 granted). The remaining authors declare no competing interests.